IDEXX LABORATORIES INC /DE (IDXX) Risk Factors

Recent key developments

Concrete developments — dated events, named agreements and instruments, legal proceedings — that IDEXX LABORATORIES INC /DE surfaced in its latest filing.

• IDEXX announced a planned CEO transition in May 2026 on January 13, 2026.May 2026
• Maine prohibits sale of non-exempt products with intentionally-added PFAS after January 1, 2032, unless an unavoidable use determination is made.January 1, 2032
• The European Union Artificial Intelligence Act will become fully effective in August 2026, with some provisions effective February 2025.August 2026
• Japan enacted AI-related legislation in May 2025.May 2025
• VCA Inc., wholly-owned by Mars, Incorporated, operates reference laboratories and sells veterinary point-of-care diagnostic instruments, competing with IDEXX.
• Major corporate hospital owners in the U.S. include Mars, Incorporated (owner of Banfield Pet Hospitals, Blue Pearl Veterinary Partners, and VCA Inc.) and National Veterinary Associates, which leverage scale for favorable pricing and may shift purchases to competitors.
• The EU-U.S. Data Privacy Framework adequacy decision adopted in July 2023 will be reviewed by the European Court of Justice.July 2023
• IDEXX is subject to the European Union’s Corporate Sustainability Reporting Directive, California’s Climate Corporate Data Accountability Act, and California’s Climate-Related Financial Risk Act, which impose specific disclosure obligations.
• During 2025, IDEXX's stock price ranged from a low of $361.04 to a high of $766.68.2025
• In 2025, 36% of overall revenue and 34%, 81%, and 50% of CAG, LPD, and Water revenues came from outside the U.S.2025